Market cap
₹3,964 Cr
Recently Viewed
Clear AllNSE: GUJTHEM | BSE: 506879
₹363.58
₹-12.06
(-3.21%)
As on 30-Apr-2026IST
Market cap
₹3,964 Cr
Revenue (TTM)
₹159 Cr
P/E Ratio
82.9
P/B Ratio
14.3
Div. Yield
0.2 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹48 Cr
ROE
21.7 %
ROCE
27.5 %
Industry P/E
37.77
EV/EBITDA
53.6
Debt to Equity
0.1
Book Value
₹25.4
EPS
₹4.4
Face value
1
Shares outstanding
108,965,265
CFO
₹259.18 Cr
EBITDA
₹377.10 Cr
Net Profit
₹282.67 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gujarat Themis
| -17.7 | 44.4 | 17.4 | 27.7 | -- | -- | -- |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gujarat Themis
|
363.6 | 3,963.6 | 159.3 | 47.8 | 39.0 | 18.6 | 82.9 | 14.3 |
| 376.3 | 3,423.1 | 2,521.8 | 202.5 | 9.6 | 14.3 | 16.9 | 2.3 | |
| 1,038.2 | 12,733.9 | 2,512.3 | 543.7 | 28.3 | 19.3 | 23.4 | 4.0 | |
| 444.6 | 7,694.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 26.2 | 5.9 | |
| 1,142.0 | 11,927.8 | 1,158.7 | 309.6 | 31.9 | 17.3 | 38.2 | 6.3 | |
| 1,680.1 | 31,850.1 | 8,850.1 | 894.8 | 15.2 | 19.8 | 36.6 | 6.4 | |
| 15,003.0 | 19,243.2 | 1,575.1 | 179.1 | 14.9 | 11.4 | 107.4 | 11.6 | |
| 2,295.0 | 3,799.8 | 707.5 | 115.2 | 17.8 | 19.4 | 33 | -- | |
| 899.2 | 4,138.8 | 588.5 | 102.9 | 22.1 | 12.7 | 40.7 | 4.9 | |
| 211.9 | 5,585.6 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 8.4 |
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of... tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India. Read more
Incorporated
1981
Chairman
Dinesh S Patel
Managing Director
Sachin D Patel
Headquarters
Valsad Dist, Gujarat
Website
Looking for more details about Gujarat Themis Biosyn Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Gujarat Themis Biosyn Ltd is ₹363.58 (NSE) and ₹363.75 (BSE) as of 30-Apr-2026 IST. Gujarat Themis Biosyn Ltd has given a return of 27.71% in the last 1 years.
The P/E ratio of Gujarat Themis Biosyn Ltd is 82.94 times as on 30-Apr-2026, a 120 premium to its peers’ median range of 37.77 times.
The P/B ratio of Gujarat Themis Biosyn Ltd is 14.31 times as on 30-Apr-2026, a 491 premium to its peers’ median range of 2.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
62.89
|
12.35
|
|
2024
|
32.42
|
14.29
|
|
2023
|
2.29
|
6.69
|
|
2022
|
1.81
|
5.73
|
|
2021
|
1.31
|
4.23
|
The 52-week high and low of Gujarat Themis Biosyn Ltd are Rs 479.00 and Rs 225.05 as of 30-Apr-2026.
Gujarat Themis Biosyn Ltd has a market capitalisation of ₹ 3,964 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Gujarat Themis Biosyn Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.